[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hookworm-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hookworm-infection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100641330","phase-3-combination-therapies-for-trichuris-trichiura-infection-in-schoolchildren-in-honduras-100641330",false,"NCT07661316","Combination Therapies for Trichuris Trichiura Infection in Schoolchildren in Honduras","Randomized, Open-Label, Assessor-Blinded Clinical Trial of Combination Therapies Versus Standard Treatment for Trichuris Trichiura Infection in Schoolchildren in La Moskitia, Honduras","AIM-T","Inclusion Criteria:\n\n* Trichuris trichiura infection documented by quantitative real-time PCR (qPCR) performed within 30 days prior to randomization.\n* Age 6 to 15 years inclusive.\n* Written informed consent provided by a parent or legal guardian. Assent provided by children aged 9 years or older, according to local ethical requirements.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to albendazole or ivermectin.\n* Receipt of an anthelmintic treatment (albendazole, mebendazole, or ivermectin) within 3 months prior to enrollment.\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Severe comorbidity at the investigator's discretion (e.g., diarrhea, tuberculosis, or malaria).\n* Body weight \\\u003C15 kg.\n* Positive pregnancy test or refusal to undergo pregnancy testing in post-menarcheal girls and female adolescents of childbearing potential.","ALL","6 Years","15 Years",{"count":21,"type":22},368,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this Phase III clinical trial is to evaluate the efficacy, safety, and acceptability of different treatment regimens for Trichuris trichiura infection in schoolchildren aged 6 to 15 years living in La Moskitia, Honduras, an area with a high burden of soil-transmitted helminth infections.\n\nThe main questions it aims to answer are:\n\n* Are combination treatments of albendazole and ivermectin more effective than albendazole alone for treating Trichuris trichiura infection?\n* Does a fixed-dose combination (FDC) of albendazole and ivermectin achieve cure rates comparable to co-administration of the two drugs?\n* How effective are the different treatment regimens against other soil-transmitted helminths, including Strongyloides stercoralis?\n* What adverse events occur following treatment with the different regimens?\n* How acceptable are the different treatment regimens to children and their caregivers?\n\nResearchers will compare four treatment groups: placebo, albendazole alone, albendazole plus ivermectin, and a fixed-dose combination of albendazole plus ivermectin.\n\nParticipants will:\n\n* Be randomly assigned to one of the four treatment groups.\n* Receive a single dose of the assigned treatment.\n* Provide stool samples before treatment and approximately 21 days after treatment.\n* Undergo laboratory testing using quantitative real-time PCR (qPCR) to detect and quantify helminth infections.\n* Be monitored for adverse events after treatment.\n* Complete acceptability assessments together with their caregivers.\n\nThe study will provide evidence on the efficacy, safety, and acceptability of a fixed-dose combination of albendazole and ivermectin and its potential use as a simplified treatment strategy for the control of soil-transmitted helminth infections in endemic settings.",[28,29,30,31,32],"Trichuriasis","Strongyloidiasis","Ascariasis","Hookworm Infection","Soil-Transmitted Helminthiasis",[34,35,36,37,38,39,40],"HONDURAS","TRICHURIS TRICHIURA","IVERMECTIN","MOSKITIA","SCHOOL AGE CHILDREN","SOIL TRANSMITTED HELMINTHIASIS","ALBENDAZOLE AND IVERMECTIN FIXED DOSE COMBINATION","NOT_YET_RECRUITING","2026-06-18",{"date":44,"type":45},"2026-06-23","ACTUAL",{"date":47,"type":22},"2026-11-01",{"date":49,"type":22},"2027-05-31",{"name":51,"class":52},"Mundo Sano Foundation","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":53},"100577588","phase-3-efficacy-and-safety-of-emodepside-in-participants-with-soil-transmitted-helminth-infections-100577588","NCT06800248","Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections","A Phase III Single-center, Randomized, Double-Blinded, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of Emodepside Compared to Multiple Doses of Mebendazole in Adolescent and Adult Participants With Soil-transmitted Helminthiasis","TREMO-Siargao","Inclusion Criteria:\n\n1. Male or non-pregnant (confirmed by a negative serum pregnancy test) and non-breastfeeding female participants aged 12 years and older.\n2. T. trichiura as a single infection or co-infection with hookworm and\u002For A. lumbricoides, confirmed by presence of T. trichiura eggs assessed by Kato-Katz thick smears from two stool samples (infection intensity defined as number of eggs per gram of stool (EPG): (1) light (1-999 EPG), (2) moderate to heavy (≥1000 EPG).\n3. A minimum infection intensity of 24 eggs per gram of stool at baseline and at least two positive slides out of the four slides assessed at baseline.\n4. Written informed consent signed by the participant and\u002For legally authorized representative(s) according to the participant's age as established per local regulations. In addition, participant's assent is required as applicable by local laws and regulations for adolescents of 12-17 years of age.\n5. Women of childbearing potential must agree to use an effective, culturally appropriate contraceptive measure from at least 28 days prior to first dosage for hormonal contraceptives only and for non-hormonal contraceptive measures from screening Visit 2 until End of Study Visit.\n\nExclusion Criteria:\n\n1. Presence of any systemic illnesses, renal and\u002For hepatic impairment, any other acute or chronic health conditions or congenital disorders which, in the opinion of the Investigator, would make the participant unsuitable for participation in a clinical study or may interfere with the efficacy, safety, and\u002For pharmacokinetic (PK) evaluation of the study drug.\n2. Any of the following:\n\n   1. Platelet \\\u003C75,000\u002Fmm3\n   2. Alanine Aminotransferase (ALT) or Serum Glutamic Pyruvic Transaminase (SGPT) \\>3x upper limit of normal (ULN)\n   3. Total bilirubin \\>2xULN\n   4. Estimated Glomerular Filtration Rate (eGFR) \\\u003C90 ml\u002Fmin\u002F1.73 m2 (adolescents) or estimated creatinine clearance (CrCl) \\\u003C90 ml\u002F min (adults)\n3. Treatment with the following anthelminthic drugs: albendazole, mebendazole, ivermectin, within 28 days before the first dose of study intervention or planned before End of Study Visit.\n4. Use of sensitive CYP3A4 substrates within 14 days before the start of the first study intervention and until at least 14 days after the last administration of study intervention.\n5. Treatment with metronidazole within 2 days before the first dose of study intervention or planned before 24 hours after last administration of study intervention.\n6. Previous assignment to a study intervention for another study planned to be administered during the period the participant is enrolled in this study (from date of informed consent to last follow-up).\n7. Known allergy\u002Fhypersensitivity to mebendazole and\u002For emodepside","12 Years",{"count":64,"type":22},315,[25],"This study aims to assess the efficacy and safety of emodepside compared to mebendazole in adults and adolescents infected with T. trichiura, either as single infection or co-infections with hookworm and\u002For A. lumbricoides.",[68,31,69],"Trichuris Trichiura; Infection","Ascaris Lumbricoides Infection",[71,72,73,74,75,76,77,78,79,80,81],"Trichuris trichiura","Ascaris lumbricoides","STH","Efficacy","Safety","Hookworm","Emodepside","Soil-transmitted helminths","Roundworm","Whipworm","Mebendazole","2026-06-10",{"date":84,"type":45},"2026-06-11",{"date":86,"type":22},"2026-09",{"date":88,"type":22},"2027-08",{"name":90,"class":52},"Swiss Tropical & Public Health Institute",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":98,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":107,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":53},"100204653","phase-1-experimental-infection-of-hookworm-nave-adults-with-dermally-applied-infectious-necator-americanus-hookworm-larvae-100204653","NCT01940757","Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae","An Experimental Infection Study of Dermally-applied Infectious Necator Americanus Hookworm Larvae in Hookworm-naïve Adults","Inclusion Criteria:\n\n* Males or females between 18 and 45 years, inclusive.\n* Good general health as determined by means of the screening procedure.\n* Available for the duration of the trial (6 months).\n* Willingness to participate in the study as evidenced by signing the informed consent document.\n\nExclusion Criteria:\n\n* Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).\n* Participant unwilling to use reliable contraception methods while participating in the study (if female and not surgically sterile, abstinent or at least 2 years post-menopausal).\n* Currently lactating and breast-feeding (if female).\n* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and\u002For laboratory studies.\n* Known or suspected immunodeficiency.\n* Laboratory evidence of liver disease (alanine aminotransferase \\[ALT\\] greater than 1.25-times the upper reference limit).\n* Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing).\n* Laboratory evidence of hematologic disease (hemoglobin \\\u003C11.5 g\u002Fdl \\[females\\] or \\\u003C12.5 g\u002Fdl \\[males\\]; absolute leukocyte count \\\u003C3.6 or \\>10.7 x 103\u002Fmm3; absolute neutrophil count \\[ANC\\] \\\u003C1.7 x 103\u002Fmm3; absolute lymphocyte count \\\u003C0.7 x 103\u002Fmm3; or platelet count \\\u003C140 x 103\u002Fmm3).\n* History of iron deficiency anemia.\n* History of hypoalbuminemia.\n* Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit).\n* Serum glucose (random) greater than 1.2-times the upper reference limit.\n* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.\n* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.\n* History of a severe allergic reaction or anaphylaxis.\n* Severe asthma as defined by the need for daily use of inhalers or emergency clinic visit or hospitalization within 6 months of the volunteer's expected Day 0 of the study.\n* Positive ELISA for hepatitis B surface antigen (HBsAg).\n* Positive confirmatory test for HIV infection.\n* Positive confirmatory test for hepatitis C virus (HCV) infection.\n* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of the volunteer's expected Day 0 of this study or planned use during the study.\n* Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected Day 0 of the study.\n* Receipt of blood products within the past 6 months.\n* Known allergy to amphotericin B or gentamicin.\n* History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area.",true,"18 Years","45 Years",{"count":102,"type":22},35,[104],"PHASE1","An experimental hookworm infection model is being developed to provide early proof-of-concept that a hookworm vaccine targeting the blood-feeding pathway of adult hookworms is feasible and efficacious. The proposed model consists of vaccinating healthy, hookworm-naïve adults with a candidate hookworm vaccine, followed by challenging them with the investigational product, Necator americanus Larval Inoculum to assess the effect of vaccination on infection. The first proposed study will be a feasibility study that will consist of administering different doses of the Necator americanus Larval Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of infectious larvae) that is safe, well-tolerated and results in consistent infection.",[31],[108,31,109],"Necator americanus","Experimental challenge infection","RECRUITING","2026-05-14",{"date":113,"type":45},"2026-05-18",{"date":115,"type":45},"2015-01",{"date":117,"type":22},"2027-12",{"name":119,"class":52},"Baylor College of Medicine"]